Assertio Therapeutics Inc - Asset Resilience Ratio
Assertio Therapeutics Inc (ASRT) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Assertio Therapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Assertio Therapeutics Inc's Asset Resilience Ratio has changed over time. See ASRT net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Assertio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ASRT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.86 Million | 17.92% |
| Total Liquid Assets | $37.86 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Assertio Therapeutics Inc maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Assertio Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Assertio Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Assertio Therapeutics Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Assertio Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.92% | $53.18 Million | $266.97 Million | +2.55pp |
| 2024-12-31 | 17.37% | $49.47 Million | $284.73 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $286.42 Million | -- |
| 2020-12-31 | 0.52% | $1.58 Million | $303.27 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $932.87 Million | -- |
| 2017-12-31 | 0.12% | $1.21 Million | $1.04 Billion | -4.76pp |
| 2016-12-31 | 4.87% | $59.71 Million | $1.23 Billion | -3.10pp |
| 2015-12-31 | 7.97% | $108.68 Million | $1.36 Billion | -1.98pp |
| 2014-12-31 | 9.95% | $70.77 Million | $711.07 Million | +4.59pp |
| 2013-12-31 | 5.36% | $27.26 Million | $508.65 Million | -21.28pp |
| 2012-12-31 | 26.64% | $37.74 Million | $141.65 Million | -11.14pp |
| 2011-12-31 | 37.78% | $62.11 Million | $164.37 Million | -17.17pp |
| 2010-12-31 | 54.95% | $47.83 Million | $87.03 Million | +8.08pp |
| 2009-12-31 | 46.87% | $42.92 Million | $91.58 Million | -16.16pp |
| 2008-12-31 | 63.03% | $59.93 Million | $95.08 Million | +14.56pp |
| 2007-12-31 | 48.47% | $39.09 Million | $80.64 Million | +16.19pp |
| 2006-12-31 | 32.28% | $16.98 Million | $52.62 Million | -45.32pp |
| 2005-12-31 | 77.60% | $51.51 Million | $66.38 Million | +2.60pp |
| 2004-12-31 | 75.00% | $17.15 Million | $22.87 Million | +24.24pp |
| 2003-12-31 | 50.76% | $24.21 Million | $47.69 Million | +13.30pp |
| 2002-12-31 | 37.47% | $8.68 Million | $23.18 Million | +7.46pp |
| 2000-12-31 | 30.01% | $2.62 Million | $8.73 Million | +14.27pp |
| 1999-12-31 | 15.74% | $3.53 Million | $22.43 Million | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more